• Official websites use .govA.govwebsite belongs to an official government organization in the United States. • Secure .gov websites use HTTPSAlock(LockA locked padlock) orhttps://means you’ve safely connected to the .gov website. • Share sensitive information only on official, secure websites. • https://www.nist.gov/news-events/news/2025/09/nists-living-reference-material-could-accelerate-rd-lifesaving-biological NIST’s ‘Living Reference Material’ Could Accelerate R&D of Lifesaving Biological Drugs Share A fast-growing category of drugs called monoclonal antibodies offers advanced treatments for breast cancer, rheumatoid arthritis, colorectal cancer and many other conditions. • To support drug manufacturers, NIST researchers have developed the first living reference material that produces monoclonal antibodies. • The NIST reference material, called NISTCHO, will help the biopharmaceutical industry develop new drugs more quickly and ensure that they are safe and effective.
Article Summaries:
- NIST has created a “living” reference material-engineered Chinese hamster ovary (CHO) cells that continuously produce a standard monoclonal antibody (NISTmAb). In partnership with MilliporeSigma and NIIMBL, the material allows biopharmaceutical companies to monitor how cell‑culture conditions, bioreactor design, purification, and storage affect antibody quality, offering a direct tool for process optimization and quality assurance. The living reference also supports equipment developers, analytical hardware makers, and workforce training. With the global monoclonal‑antibody market projected to grow from $249 billion in 2024 to over $619 billion by 2031, the new resource aims to keep U.S. industry at the forefront of lifesaving drug development.
Sources: